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Background: Survival rates in lung cancer in England are significantly lower than in many similar countries. A range of Be Clear on
Cancer (BCOC) campaigns have been conducted targeting lung cancer and found to improve the proportion of diagnoses at the
early stage of disease. This paper considers the cost-effectiveness of such campaigns, evaluating the effect of both the regional
and national BCOC campaigns on the stage distribution of non-small-cell lung cancer (NSCLC) at diagnosis.
Methods: A natural history model of NSCLC was developed using incidence data, data elicited from clinical experts and model
calibration techniques. This structure is used to consider the lifetime cost and quality-adjusted survival implications of the early
awareness campaigns. Incremental cost-effectiveness ratios (ICERs) in terms of additional costs per quality-adjusted life-years
(QALYs) gained are presented. Two scenario analyses were conducted to investigate the role of changes in the ‘worried-well’
population and the route of diagnosis that might occur as a result of the campaigns.
Results: The base-case theoretical model found the regional and national early awareness campaigns to be associated with QALY
gains of 289 and 178 QALYs and ICERs of d13 660 and d18 173 per QALY gained, respectively. The scenarios found that increases
in the ‘worried-well’ population may impact the cost-effectiveness conclusions.
Conclusions: Subject to the available evidence, the analysis suggests that early awareness campaigns in lung cancer have the
potential to be cost-effective. However, significant additional research is required to address many of the limitations of this study.
In addition, the estimated natural history model presents previously unavailable estimates of the prevalence and rate of disease
progression in the undiagnosed population.
Survival rates in lung cancer in England and the United Kingdom
are significantly lower than in countries with similar levels of
expenditure on health care (Holmberg et al, 2010; Coleman et al,
2011), and have shown little improvement over the last three
decades compared with those seen in other cancers (CRUK, 2012).
The importance of diagnosing cancer at an early stage is well
understood (Richards, 2009b; DOH, 2012), with many treatment
options only effective if used early in the disease course. However,
little is known about the best way to achieve earlier diagnosis, with
most of the onus being placed on a poor level of understanding of
the symptoms of lung cancer, and a reluctance to present at
primary care among the general public. Recent government
initiatives in England have sought to raise public awareness of
the signs and symptoms of cancer to promote earlier presentation
to primary care (Richards, 2009a). A range of ‘Be Clear on Cancer’
(BCOC) campaigns have been run since the initiative’s launch in
2011, including regional and national lung cancer early awareness
campaigns (Ironmonger et al, 2014). The campaigns have been
conducted through a range of advertising mediums including
television, radio and leafleting.
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A recent publication has presented the results of these
campaigns (Ironmonger et al, 2014), finding a shift in the stage
of diagnosis of non-small-cell lung cancer (NSCLC) following the
awareness campaign and significant increases in levels of public
awareness of the symptoms of lung cancer, urgent GP referrals
for suspected lung cancer and overall diagnosis. The authors
concluded that the results may lead to improved long-term
survival, and that the assessment of the cost-effectiveness of the
interventions is an important next step. This paper reports on an
evaluation of the cost-effectiveness of both the regional pilot and
the national BCOC campaign in shifting the stage at diagnosis of
NSCLC.
To conduct such an evaluation, it is necessary to understand the
natural history of the disease in undiagnosed, and thus untreated,
patients, that is, the development and progression of cancers before
a diagnosis has been made. This can then be used to provide a
prediction of the lifetime health outcomes of the patient population
(both with and without an early awareness campaign) by taking
into account the stage and age at which diagnosis occurred. To
date, there has been no published research estimating the natural
history of undiagnosed NSCLC, largely because of the limited
evidence available (Black et al, 2006). Therefore, in addition to the
estimation of the cost-effectiveness of the early awareness
campaigns, this report details the work conducted to characterise
the natural history of untreated NSCLC, using calibration
techniques (Weinstein, 2006; Whyte et al, 2011), necessary to
inform the cost-effectiveness analysis.
MATERIALS AND METHODS
Overview. A decision-analytic model was developed to assess the
cost-effectiveness of an early awareness campaign for the signs and
symptoms of lung cancer in the English population. The model
considers the proportion of patients at each stage of disease, from
initial development of the disease before diagnosis, progression and
final diagnosis. The long-term outcomes associated with diagnosis
by stage of disease are expressed in terms of quality-adjusted life
years (QALYs) through a consideration of the mortality risk and
health-related quality of life (HRQoL) of NSCLC patients. Costs
are considered from the perspective of the UK NHS and Personal
Social Services, using 2012 prices, with costs and benefits
discounted at 3.5% per year, consistent with the approach taken
by the National Institute for Health and Care Excellence (NICE) to
value future costs and benefits at current rates (NICE, 2013).
The cost-effectiveness of the regional and national campaigns
was estimated by applying the observed shift in the incidence and
distribution of NSCLC by stages at diagnosis to the analytical
model and considering the resultant change in long-term outcomes
and costs. The same model structure was applied to both the
regional and national campaigns. To facilitate a direct comparison
of the results of the two campaigns, and to account for the lack of
an estimate of the direct cost of the regional campaign, the results
of the regional pilot were extrapolated to a national population by
weighting the results by the size of the population covered. Clearly,
this approach relies on the regional campaign approach being
similar to the national campaign and that the results of the regional
campaign can be extrapolated to a national level.
Model structure. To estimate the prognostic implications of the
awareness campaigns, it was necessary to model the natural history
of the disease, the structure of which is shown in Figure 1. The
model represents a Markov-type structure, consisting of four main
health states: no disease (specifically no NSCLC), prediagnostic
NSCLC, postdiagnostic NSCLC and mortality.
Solid black lines represent transitions that can be estimated
directly from available data. Dashed grey lines denote transitions
that are unobservable in practice owing to their occurrence before
diagnosis. Consequently, these are parameters that must be
estimated through methods of calibration, which is discussed in
the following section. The cycle length of the model, the minimum
time in which patients can move from one state to the next, is set at
1 month to account for the potentially rapid development of the
disease while not requiring an excessive level of computation.
Within each of the cancer states (pre- and postdiagnosis), there
are three stages of disease severity representing limited, advanced
and extensive disease. For the aggregated TNM staging system,
these are assumed to represent stages I and II for limited disease,
stage IIIa for advanced disease and stages IIIb and IV for extensive
disease. The development of NSCLC was not assumed to be linear,
such that the disease can develop directly from limited to extensive
stages. Although the BCOC campaigns were designed to target
those over the age of 50 years, it is clear that all ages will be exposed
to the campaign. Therefore, the evaluation considered the entire
English population over the age of 30 years, an age selected because
of the small incidence of NSCLC below it, and to reduce excessive
computational requirements.
Mortality was considered separately for NSCLC-related deaths
and other-cause deaths. NSCLC mortality was assumed to occur
only in the postdiagnosis stages of the disease under the
assumption that all patients would be diagnosed with NSCLC
before death since the incidence of lung cancer diagnosis at post
mortem without clinical diagnosis is relatively rare (estimated to be
o5% of the total incidence from the 2011 National Lung Cancer
Audit Dataset (LUCADA)) (NHSIC, 2011).
Early awareness campaign. The BCOC regional campaign was
conducted in the Midlands between October and December 2011,
using the rest of England as a control area. The regional campaign
collected data on the incidence of NSCLC diagnosis by stage, in the
campaign and control areas, before and during the campaign from
LUCADA, which collects the total incidence of NSCLC in England
(NHSIC, 2011). This allowed for a ‘difference in difference’ analysis
to be undertaken, which measures the effect of the campaign on
incidence of NSCLC, by stage, while controlling for underlying
changes in the diagnoses of disease not related to the campaign by
adjusting the change in diagnoses in the intervention area by the
change observed in the control area.
The full national campaign took place between May and July
2012. Control data were collected for all English trusts for patients
first seen between May and July 2011 and this was compared with
the campaign period. To allow for the lack of a direct control area,
this was compared with the trend in incidence in the period
February to April 2011 and February to April 2012. The full details
are available elsewhere (Ironmonger et al, 2014).
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Figure 1. Schematic of the natural history model.
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Tables 1 and 2 report the raw and percentage changes in the
incidence of diagnosis, by stage, for both campaigns in the control
and campaign groups, as well as the adjusted relative change in
stage (Ironmonger et al, 2014). The impact of the campaigns were
‘smoothed out’ by weighting the incidence at each stage by the
respective total observed incidence; this represents the underlying
change in the stage at clinical identification. Patients whose
diagnosed stage of disease was listed as unknown in LUCADA were
excluded from the analysis. This table shows that, in both
campaigns, there was a shift toward earlier diagnosis of disease.
The national campaign showed a smaller relative reduction in the
proportion of patients diagnosed at late stages of disease, but a
larger increase in stage I and II relative diagnoses. The results of the
regional campaign were scaled up to a national level to allow
comparability with the national campaign.
The relative changes were applied to the natural history model,
presented in the following section, to consider the implications of
the estimated NSCLC stage shift generated by the campaigns when
compared with no intervention for long-term costs and QALYs.
Owing to the immaturity of the data being reported from any of
the campaigns, and with no data collected after the end of the
campaign after the intervention, it was not possible to consider the
duration of effect of any early awareness campaign. The base-case
analysis assumes that the campaign only has an effect for the
period of the campaign, likely to represent a conservative
assumption of the effectiveness of the campaigns.
Model inputs. A major challenge in modelling the natural history
of NSCLC is the requirement to understand the transition of
patients in prediagnostic stages of disease, which cannot be
informed by clinical trials (Black et al, 2006). Therefore, in the
absence of observable data, model calibration techniques
(Weinstein, 2006; Whyte et al, 2011), together with the elicitation
of clinical knowledge, were used to estimate the unobservable
transition probabilities. Methods of calibration seek to make use of
all available evidence relevant to the disease in the estimation of a
set of transitions. This can include expert opinion as a source of
prior information, and observable data on the prevalence or
incidence of cancer, together with a prior expectation about the
structure of the natural history of the disease. Further details of the
calibration method as well as reporting guidelines used to structure
the model can be found elsewhere (Stout et al, 2009; Vanni et al,
2011). The calibration techniques used in this analysis have been
developed and applied elsewhere by Weinstein (2006), Whyte et al
(2011, 2012) and Whyte and Harnan (2014).
The technique uses the Metropolis–Hasting algorithm to
estimate the natural history parameters by generating multiple
sets of parameters from the posterior distribution, informed by
observed data (Whyte et al, 2011). The calibration presented here
utilised an initial set of prior probabilities elicited from expert
clinicians (Doctors Peake, Rogers and Callister acknowledged
above), and calibrated it to data on the incidence of NSCLC in
England from LUCADA (NHSIC, 2011). The results of the expert
elicitation exercise are presented in Table 3, the plausible range
reported was used to test the validity of the calibration results.
Details of the calibration method and the application of the Stout
et al (2009) checklist for reporting of calibration methods are
reported in the Supplementary Appendix.
It was assumed that the expected probability of initially
developing NSCLC increases with age, and the probability of an
individual with prediagnosis NSCLC being clinically identified
increases with the advancement of cancer stage. However, owing to
a lack of available data to power a more complex model, it was not
possible to consider the impact of sub-population effects such as
sociodemographic factors and smoking status. Similarly, while age
was assumed to impact the probability of initial development of
NSCLC, it was not assumed to affect the expected speed of
progression. The calibration resulted in the state transitions
reported in Table 4 alongside all other model inputs. The table
shows that the calibrated estimates fitted well within the expert
elicited estimates given in Table 3.
Mortality. Data on NSCLC survival were provided by the
International Cancer Benchmarking Partnership and represents
an estimate of net survival from lung cancer for the United
Kingdom by age and stage of disease. Data on other-cause age-
adjusted mortality were taken from Interim Life Tables for 2008–
2010 for England (ONS, 2011) and were adjusted to remove
mortality owing to lung cancer for each age group.
Costs. A systematic review of the costs of lung cancer was
conducted using the NHS Economic Evaluation Database (EED,
2012). The systematic review identified one published study of
relevance, Fleming et al (2008)), which estimated hospital costs
relating to lung cancer in Northern Ireland. The authors analysed
Table 1. Change in incidence and percentage change in the weighted distribution of stage of diagnosis, regional campaign
Intervention area Control area Percentage change from baseline
Stage of disease
Oct–Dec
2010
Oct–Dec
2011
Oct–Dec
2010
Oct–Dec
2011
Intervention
area (%)
Control
area (%)
Adjusted
change (%)
I and II 231 318 922 1038 10 1 9
IIIa 107 163 539 599 22 0 22
IIIb and IV 698 813 2521 2801 7 0  6
Total 1036 1294 3982 4438
Table 2. Change in incidence and percentage change in the weighted distribution of stage of diagnosis, national campaign
Campaign period (intervention) Control period (control) Percentage change from baseline
Stage of disease
May–July
2011
May–July
2012
Feb–Apr
2011
Feb–Apr
2012
Campaign
period (%)
Control
period (%)
Adjusted
change (%)
I and II 1424 1840 1395 1581 15 5 10
IIIa 859 921 857 902 4  2  2
IIIb and IV 3809 4070 3561 3773 5  2  3
Total 6092 6831 5813 6256
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the case notes of 724 patients diagnosed in 2001 for a period of 12
months following presentation by cell type and extent of disease
(limited, advanced and extensive). The severity groupings reported
in the study were assumed to be representative of the three stages
defined in the model. Costs were adjusted for inflation to a 2012
price level, and are presented in Table 4. Unfortunately, no non-
hospital costs were identified in the systematic review, and thus
were not available to inform this analysis. It is likely that the
estimate of costs used represent a significant underestimate of the
total cost to the NHS.
In addition to the costs associated with increased diagnosis and
treatment, it is important to consider the cost of the campaign
itself. Personal communication with the Department of Health
provided a cost estimate for an England-wide campaign of
d2.9million (personal communication with clinical advisors: Dr
Mick Peake, Dr Matthew Callister, Dr Trevor Rogers; personal
communication with Dr Bernard Rachet, London School of Hygine
and Tropical Medicine). This cost was used to inform both the
scaled up regional pilot and the national campaign as no estimate
of total cost of the regional campaign was available. The difficulty
in obtaining a more robust estimate or specific references to the
cost of the campaign highlight the challenges associated with a full
evaluation of such campaigns.
Health-related quality of life. A systematic review of literature on
HRQoL associated with lung cancer identified only one publica-
tion, which was suitable to inform the model based on the
following criteria: (i) estimation of HRQoL in terms of a
preference-based weighting suitable for calculating QALYs;
(ii) representative of an English setting; and (iii) reported HRQoL
by stage of disease (Sturza, 2010). This paper was used to derive the
mean HRQoL weights used in the cost-effectiveness model, as
shown in Table 4.
These HRQoL values were compared with the age-specific
HRQoL weights of the general population from the Health Survey
for England (Ara and Brazier, 2009) and applied in the model as
decrements for 5 years after initial clinical diagnosis. Long-term
survivors of the disease (i.e., beyond 5 years) were assumed to
return to the HRQoL level of the general population at that age.
The literature review failed to identify any articles in which the
impact of false diagnoses on HRQoL was quantified. Although it is
clear that a false diagnosis has the potential to hugely damage
HRQoL of a patient over a short period of time, the analysis has
Table 3. Parameter estimates derived from expert elicitation
exercise
Parameter
Expected
monthly
probability
Plausible range
(from, to)
Transition from no disease to stage I and II disease
Age 30–49 years 0.004 10 3 0.001–0.01103
Age 50–69 years 0.07 10 3 0.002–0.2103
Age 70þ years 0.25 10 3 0.1–0.75103
Prediagnostic transitions
Stages I and II to stage IIIa 0.05 0.03–0.5
Stages I and II to stages IIIb and IV 0.1 0.05–0.7
Stage IIIa to stages IIIb and IV 0.2 0.1–1
Probability of being diagnosed given current NHS practice
Stages I and II 0.15 0.03–0.3
Stage IIIa 0.2 0.1–0.5
Stages IIIb and IV 0.2 0.1–0.75
Table 4. Costs, HRQoL, model inputs and impact of the campaigns
Input value
Costs
Parameter Diagnosisa Treatmentb Source
Stage I and II d1035 d7889 Fleming et al (2008)
Stage IIIa d1046 d7358
Stage IIIb and IV d911 d4954
HRQoL
Stage I and II 0.825 Sturza (2010)
Stage IIIa 0.772
Stage IIIb and IV 0.573
Prediagnostic transitions
No disease to stage I and II – age 30–49 years 0.00410 3 Estimated through calibration model within the
plausible range of expert opinion
No disease to stage I and II – age 50–69 years 0.0810 3
No disease to stage I and II ndash; age 70þ years 0.1710 3
Stages I and II to stage IIIa 0.009
Stages I and II to stages IIIb and IV 0.44
Stage IIIa to stages IIIb and IV 0.007
Diagnostic transitions – precampaign
Diagnosis at stage I and II 0.0048 Estimated through calibration model within the plausible
range of expert opinion
Diagnosis at stage IIIa 0.183
Diagnosis at stage IIIb and IV 0.239
National campaign Regional campaign
Diagnostic transitions – during campaign
Diagnosis at stages I and II 0.0054 0.0054 Estimated by applying campaign results (ref. table)
to natural history model
Diagnosis at stage IIIa 0.183 0.255
Diagnosis at stage IIIb and IV 0.161 0.364
aConsists of 16 diagnostic tools.
bSurgical, chemotherapy, radiotherapy and in-patient costs.
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not incorporated these effects. The impact of such an omission on
the cost-effectiveness results is unclear, as more patients will
present the proportion of false diagnosis, which may increase or
decrease as a result of the campaign.
Analytical methods. The natural history model was used to
generate estimates of long-term expected costs and QALYs with
and without a national awareness programme. Cost-effectiveness is
expressed in terms of the ICER, a measure of the extra cost per
additional QALY gained from the campaign. This can be compared
with a cost-effectiveness threshold, which represents health forgone
as a result of other services being displaced to fund the campaign
from a limited NHS budget. The threshold used by NICE is
d20 000–30 000 per QALY gained (NICE, 2013), although recent
research suggests that this should perhaps be lower at around
d13 000 per QALY (Claxton et al, 2013).
A base-case analysis was undertaken based on the methods
outlined above. In addition, two scenarios are considered to reflect
uncertainty in the assumptions used:
(1) Size of the ‘worried-well’ population attending their GP and
receiving chest X-rays: The base-case analysis assumed that there
was no change in the size of the population visiting their GP as a
result of the campaign not diagnosing individuals with NSCLC.
However, as shown in the clinical results of the BCOC campaigns
this is unlikely (Ironmonger et al, 2014). The results of the
campaigns showed an increase in the number of presentations at
the primary care, with a 63% increase in presentation of patients
with a cough in the 8 weeks of the national trial. This scenario
considered the impact of an increase in the primary care
presentations by estimating the necessary size of the increase in
presentation of those without lung cancer that would result in the
campaign no longer being considered to be cost-effective and
compares it against findings from the campaigns. Each GP
consultation is assumed to be clinic based and last 11.7minutes
(costing d53.00) (PSSRU, 2011).
(2) Route of diagnosis: As part of the local BCOC campaigns
(DOH, 2012), several local project teams collected data on route to
diagnosis of lung cancer over the period of the campaign to
investigate whether the route to diagnosis was also affected by the
campaign. A reduction in diagnosis at emergency departments is
likely to be associated with a significant cost saving due to the large
cost per bed day of emergency care compared with presentation at
GPs. The scenario assumed a cost per accident and emergency
attendance of d129, the upper bound of the average cost per
attendance reported by a Foundation Trust Network survey (FTN,
2012), as the only measurable cost saving. The additional cost of a
GP consultation reported in the first scenario is also included as
the alternative site of presentation.
RESULTS
Natural history estimates. In addition to informing a cost-
effectiveness analysis, the natural history model was used to
estimate the incidence and prevalence of undiagnosed cancers and
the expected rate of cancer development and diagnosis in England.
Table 5 reports the predicted annual incidence and prevalence of
undiagnosed NSCLC cases in England, as well as the percentage of
the English population that this represents. The age group 85þ
years was excluded from the analysis owing to a poor calibration
performance of the model in this age group, details of the model fit
to the calibrated data can be found in the Supplementary
Appendix. These estimates indicate that the model predicted a
relatively high prevalence of undiagnosed stage I and II NSCLCs
in England (0.24% of the population aged 30–84 years). The
apparently low prevalence of undiagnosed stage IIIa disease (1110
of 79 238 undiagnosed cases) is likely explained by the short mean
duration of stay in this stage of disease as shown by the high
estimated probability of transiting from the state (see Table 4).
Base-case cost-effectiveness. Table 6 shows the estimated costs
(campaign, diagnosis and treatment), incremental QALYs and
resultant ICERs without an intervention and with the regional and
national campaigns. The table shows that in both cases the large
campaign cost (d2.9 million) was complimented by a relatively
small increase in costs of diagnosis and treatment.
The mortality and HRQoL implications of the campaigns can be
combined to consider the QALY implications. In the regional
campaign (scaled up to a national level), an incremental gain of
289 QALYs was estimated, and 178 QALYs as a result of the
national campaign, as shown in Table 6. These results give ICER of
d13 660 per QALY gained for the regional campaign and d18 173
for the national campaign, which are below NICE’s threshold range
of d20 000–30 000 per QALY, suggesting that the early awareness
campaign was potentially cost-effective to the UK NHS (NICE,
2013). The inclusion of the unstaged patients from the LUCADA
data in the stage IIIb and IV patient group had only a small impact
on the ICER.
Scenario analysis. As discussed above, two scenario analyses were
considered to evaluate the implications of the limitations of the
base-case analysis. The first scenario found that, over the period of
the campaigns, an increase in unnecessary GP consultations of
roughly 18 000 in the national and 35 000 in the regional analyses
would have had to be caused by the campaigns to make them not
cost-effective at a threshold of d20 000. Recent published results
show that, across 486 GP practices (of almost 8000 in England),
21 930 additional GP presentations for coughs occurred during the
Table 5. Estimated incidence and prevalence of prediagnosis NSCLC
Prevalence of prediagnosis NSCLC
Age group (years)
Annual incidence of new
(prediagnosis) NSCLC Stage I and II Stage IIIa Stage IIIb and IV
30–54 2020 (0.01%) 5314 (0.03%) 79 (0.00%) 284 (0.00%)
55–59 2228 (0.07%) 5509 (0.19%) 81 (0.00%) 288 (0.01%)
60–64 3710 (0.12%) 11 401 (0.36%) 170 (0.01%) 615 (0.02%)
65–69 3758 (0.15%) 13 368 (0.55%) 200 (0.01%) 731 (0.03%)
70–74 3425 (0.17%) 14 892 (0.73%) 224 (0.01%) 826 (0.04%)
75–79 2423 (0.15%) 13 318 (0.80%) 201 (0.01%) 747 (0.04%)
80–84 1438 (0.11%) 10 258 (0.82%) 155 (0.01%) 577 (0.05%)
Total (30–84) 19 002 (0.06%) 74 060 (0.24%) 1110 (0.00%) 4068 (0.01%)
Values within parentheses represent the percentage of age-specific population.
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course of the national campaign (Ironmonger et al, 2014). Clearly,
these results suggest that the campaigns are unlikely to be cost-
effective if the costs of the worried well population are taken into
account. However, this scenario fails to attribute any health benefit
of these worried-well patients attending the GP consultations, and
as such must be interpreted carefully and warrants further
research.
The second scenario found that a saving in the region of 50 000
emergency admissions would have had to occur as a result of the
campaigns for them to become cost neutral, that is, as much was
saved from reduced emergency admissions as the additional costs
incurred by the campaign to the NHS. This is far more than the
total number of diagnoses of lung cancer during this period.
Ironmonger et al (2014) reported a small decrease in the rate of
presentation at emergency departments of 1.9%; however, this does
not appear to have been sustained and this analysis represents an
approximate estimation of the factors involved.
DISCUSSION
This evaluation has made a significant step forward in our
understanding of the potential cost-effectiveness of campaigns to
improve early awareness of persistent cough as a symptom of
NSCLC. The base-case results suggest that the national campaign
could be seen as cost-effective relative to the current NICE
threshold range (NICE, 2013). However, the estimates of the ICERs
are above the recently estimated cost-effectiveness thresholds
empirically estimated from the NHS data (Claxton et al, 2013).
The authors are, however, keen to highlight significant
limitations in the analysis, and areas where further research is
vital. First, the analysis represents a deterministic approach, with
no empirical consideration of the scale or impact of the uncertainty
in the natural history model or the results of the early awareness
campaign. This was owing to the inability to quantify uncertainty
in the effects of an early awareness campaign. Although the
regional and national campaigns represent two realisations of the
uncertainty, it is not possible to know with certainty the full range
of possible outcomes. Therefore, the results presented represent the
most robust mean predictions but should not be considered to be
certain.
Second, the model fails to take into account important lifestyle
and sociodemographic factors known to be associated with the
prevalence of lung cancer. Although the incorporation of such
factors will not impact the nationwide conclusions drawn from the
analysis, it is likely that specific subgroups are associated with very
different transition probabilities, and as such the cost-effectiveness
of campaigns targeting such groups will vary.
Finally, significant further research is needed to provide more
complete and robust estimates of a range of the parameters used to
inform this research, primarily the costs associated with lung
cancer diagnosis and treatment, the impact of such campaigns on
other diagnosis and presentations, and the duration of effect of
informative campaigns.
An inevitable implication of the unobservable nature of the
natural history model is the difficulty in assessing the validity of the
estimated parameters. This is compounded by the lack of suitable
data to inform the calibration method, with a reliance on clinical
expertise and data collected by the LUCADA data set. Several
sources of additional information were explored including the use
of lung cancer screening trials (the DANTE, ITALUNG and
DSCST trials), which have the potential to strengthen the estimate
of the underlying prevalence of undiagnosed disease. However, as
the primary aim of the early awareness campaigns is to reach
similar levels of early stage diagnosis as other comparable nations,
the use of non-English data to inform the model is likely to
introduce significant bias into the natural history model and thus
any inference of cost-effectiveness. The use of data from the UK
Lung Cancer Screening Trial (UKLS) (Baldwin et al, 2011; Field
et al, 2011) could be used in the future to strengthen the estimates
presented, subject to challenges associated with the use of data
from screening trials.
This analysis does, however, represent the first attempt to define
the natural history of the disease in its prediagnosis state. This is
informative for future public health initiatives as the estimates
provide an idea of the undiagnosed diseased population, and
therefore the size, stage distribution and age of the population that
has the potential to benefit from future public health initiatives.
Although this study found clear evidence of a positive impact of
both campaigns, the significant uncertainty associated with many
of the model inputs used makes a definitive statement of cost-
effectiveness challenging. Further research is needed around many
of the variables used in this study if further campaigns to improve
the awareness of the signs and symptoms of lung cancer are to be
justified as cost-effective.
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